ArticleJournal of translational internal medicine2026
Focal adhesion kinase inhibition enhances response to checkpoint immunotherapy in hepatocellular carcinoma.
Article in Journal of translational internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis.Molecular biomedicine · 2026Article
- MTHFD1L in muscle invasive bladder cancer: a multi-cohort study on prognosis and therapeutic response.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Despite the remarkable efficacy of immune checkpoint inhibitors (ICIs) in cancer therapy, their clinical benefit in hepatocellular carcinoma (HCC) remains limited. Focal adhesion kinase (FAK) plays a pivotal oncogenic role in various tumors by promoting angiogenesis, tumor proliferation, and immunosuppression. Therefore, targeting FAK represents a promising strategy to enhance immunotherapy outcomes in HCC. Methods: We analyzed RNA-sequencing data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to compare Results: FAK was highly expressed and frequently amplified in HCC tumors, which predicted worse pathological features of patients. A notable feature of FAK-positive HCC tumors was an adverse immune microenvironment marked by a depletion of CD8 Conclusions: FAK inhibitors can enhance the sensitivity of HCC to anti-PD-1 therapy by inhibiting angiogenesis and fibrosis and promoting CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.